YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
114 hedge funds and large institutions have $1.11B invested in Y-mAbs Therapeutics in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 34 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
8% more funds holding
Funds holding: 106 → 114 (+8)
1.9% more ownership
Funds ownership: 53.57% → 55.47% (+1.9%)
Holders
114
Holding in Top 10
4
Calls
–
Puts
–
Top Buyers
| 1 | +$15.9M | |
| 2 | +$13.1M | |
| 3 | +$11.7M | |
| 4 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$10.9M |
| 5 |
Goldman Sachs
New York
|
+$6.7M |
Top Sellers
| 1 | -$13.1M | |
| 2 | -$10.7M | |
| 3 | -$5.32M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.29M |
| 5 |
Axa
Paris,
France
|
-$4.68M |